Foamix Pharmaceuticals Ltd. | Mutual Funds
Mutual Funds that own Foamix Pharmaceuticals Ltd.
AXA Framlington Health Fund
802,186
1.97%
0
0.64%
04/30/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
635,300
1.56%
0
0.16%
06/30/2018
516,598
1.27%
0
0.42%
03/31/2018
iShares Nasdaq Biotechnology ETF
467,292
1.14%
-6,111
0.03%
09/06/2018
Franklin Small Cap Growth Fund
457,580
1.12%
0
0.09%
03/31/2018
Franklin Biotechnology Discovery Fund
371,100
0.91%
0
0.14%
03/31/2018
Tekla Healthcare Investors
289,660
0.71%
0
0.15%
12/31/2017
Driehaus Micro Cap Growth Fund
227,869
0.56%
6,031
0.26%
06/30/2018
BNY Mellon Small Cap Multi Strategy Fund
171,730
0.42%
0
0.14%
05/31/2018
AXA World Funds - Framlington Health
120,748
0.3%
9,819
0.62%
12/31/2017
| Address |
2 Holzman Street
Rehovot HM 76704
Israel
|
|
Employees
|
- |
| Website |
http://www.foamixpharma.com |
| Updated |
07/08/2019 |
| Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. |
